Erika Hamilton, MD, FASCO· @ErikaHamilton9 · X·· 2 天前评分90
正文 · 机器翻译
TALENT- 新辅助治疗中 T-DXd 用于 HR+/HER2-low #bcsm
RCB0/1：
🔹 T-DXd 单药：16%
🔹 T-DXd + anastrozole：17%
🔹 T-DXd → TC 化疗：17%
*未满 8 个周期时无 pCR
尽管 ORR 高达约 66%，pCR 仍然很低！我们知道 HR+ 患者无法获得较高的 pCR 率，但结果仍令人失望
#ESMO26 #ESMOAmbassadors
1014 浏览 · 11 赞 · 8 转发 · 2 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org帖内回复
- Rebecca Shatsky, MD@Dr_RShatsky
@ErikaHamilton9 Why do we have trials that include luminal A breast cancer patients getting chemo?? 😕#Breastcancer
- Erika Hamilton, MD, FASCO@ErikaHamilton9
https://www.esmo.org/insights-by-esmo/all-news/low-rates-of-pathological-complete-response-reported-with-trastuzumab-deruxtecan-in-early-breast-cancer #ESMO26 #ESMOAmbassadors
来源：Erika Hamilton, MD, FASCO · x.com